ROIV - Company ID 0001635088
The table below shows Roivant Sciences Ltd.'s balance sheet line items across its last 4 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash & equivalents | $1.42B | $2.72B | $6.54B | $2.06B |
| Short-term investments | $2.87B | $2.17B | - | - |
| Receivables | - | - | - | - |
| Inventory | - | - | $35.25M | - |
| Total current assets | $5.17B | $5.00B | $6.73B | $2.15B |
| Property, plant & equipment | $11.99M | $12.06M | $19.06M | $25.91M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Goodwill | - | - | - | - |
| Total assets | $5.71B | $5.44B | $7.22B | $2.59B |
| Accounts payable | $18.00M | $23.69M | $53.23M | $34.58M |
| Total current liabilities | $281.24M | $149.41M | $266.76M | $184.37M |
| Long-term debt | - | - | $430.59M | $210.03M |
| Total liabilities | $416.27M | $249.74M | $773.95M | $523.70M |
| Retained earnings | -$501.81M | $116.06M | $576.17M | -$2.76B |
| Total equity | $4.53B | $4.69B | $5.97B | $1.66B |